Xeris Biopharma (NASDAQ:XERS) Receives “Neutral” Rating from Piper Sandler

Piper Sandler restated their neutral rating on shares of Xeris Biopharma (NASDAQ:XERS) in a report issued on Friday morning,Benzinga reports. They currently have a $4.00 price objective on the stock, up from their prior price objective of $3.00.

Other research analysts have also issued reports about the stock. HC Wainwright reiterated a “buy” rating and set a $8.00 price target (up from $6.60) on shares of Xeris Biopharma in a research note on Friday. Jefferies Financial Group reiterated a “buy” rating and set a $6.00 price target (up from $4.00) on shares of Xeris Biopharma in a research note on Wednesday, January 29th.

Xeris Biopharma Stock Up 2.7 %

Shares of Xeris Biopharma stock opened at $4.24 on Friday. Xeris Biopharma has a 52-week low of $1.69 and a 52-week high of $4.50. The company’s 50-day simple moving average is $3.55 and its 200-day simple moving average is $3.24. The firm has a market cap of $632.10 million, a price-to-earnings ratio of -9.42 and a beta of 2.32.

Institutional Trading of Xeris Biopharma

A number of institutional investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. boosted its holdings in Xeris Biopharma by 1.7% during the fourth quarter. Vanguard Group Inc. now owns 7,899,063 shares of the company’s stock worth $26,778,000 after buying an additional 133,738 shares in the last quarter. Geode Capital Management LLC boosted its holdings in Xeris Biopharma by 0.5% during the fourth quarter. Geode Capital Management LLC now owns 3,351,426 shares of the company’s stock worth $11,364,000 after buying an additional 17,956 shares in the last quarter. AIGH Capital Management LLC boosted its holdings in Xeris Biopharma by 17.8% during the fourth quarter. AIGH Capital Management LLC now owns 2,574,846 shares of the company’s stock worth $8,729,000 after buying an additional 389,192 shares in the last quarter. Renaissance Technologies LLC lifted its holdings in shares of Xeris Biopharma by 31.3% in the fourth quarter. Renaissance Technologies LLC now owns 2,098,840 shares of the company’s stock valued at $7,115,000 after purchasing an additional 500,120 shares in the last quarter. Finally, Millennium Management LLC lifted its holdings in shares of Xeris Biopharma by 34.8% in the fourth quarter. Millennium Management LLC now owns 1,948,552 shares of the company’s stock valued at $6,606,000 after purchasing an additional 502,853 shares in the last quarter. Hedge funds and other institutional investors own 42.75% of the company’s stock.

About Xeris Biopharma

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.